ISSOIRE, France--(BUSINESS WIRE)--Regulatory News:
BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, announces today that the brokerage firm Gilbert Dupont has initiated analyst coverage of BIOCORP with “Buy “ rating and €26,90 price target.
The detailed note is available in the shareholders' area on the company's website (https://biocorpsys.com/investisseurs/espace-actionnaires/). Gilbert Dupont joins Bryan Garnier, whose analyst also initiated coverage on the company with a “buy “ rating in April 2020.
All reports on BIOCORP prepared by analysts represent the views of those analysts and not necessarily those of BIOCORP. BIOCORP is not responsible for the content, accuracy, or timing of analyst reports.
This information does not constitute an offer to sell or subscribe, or the solicitation of an order to buy or subscribe for securities in France, Europe, the US or any other country.
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
Follow us on Twitter @BIOCORPSystems